This clinical trial is focused on studying certain types of advanced cancers that affect the ovaries, fallopian tubes, or the lining of the abdomen, known as the peritoneum. These cancers are specifically referred to as high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study is investigating a treatment called Radspherin, which is a type of therapy that involves injecting a special substance into the abdominal area. This substance contains radium-224, a radioactive element, which is absorbed in tiny particles of calcium carbonate. The aim is to see if this treatment can help patients who are scheduled to receive chemotherapy and surgery to remove as much of the cancer as possible.

The purpose of the study is to compare how long patients can live without their cancer getting worse when treated with Radspherin compared to those who do not receive this treatment. Patients participating in the study will be randomly assigned to either receive the treatment or not. The study will follow their progress over time to see how the treatment affects their cancer. This includes regular check-ups and imaging tests like CT or MRI scans to monitor the cancer’s status.

Throughout the study, researchers will also look at other factors, such as overall survival rates, the time until further cancer treatment is needed, and changes in certain cancer markers in the blood. Additionally, the study will assess how the treatment impacts patients’ quality of life through questionnaires. The goal is to gather comprehensive data to understand the potential benefits and effects of Radspherin in treating these advanced cancers.